Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors

Journal of Surgical Oncology

Volumn 102, Issue 8, 2010, Pages 898-908

  Legolvan, Mark P ^a   Resnick, Murray ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

angiogenesis; cadherins; epithelial mesenchymal transformation EMT; integrins; miRNA

Indexed keywords

ANGIOGENESIS; CANCER MORTALITY; CELL INTERACTION; CELL MIGRATION; COLORECTAL CANCER; HUMAN; LIVER METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 78650648695     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21817     Document Type: Review

References (133)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Horner MJ, Ries LAG, Krapcho M, et al.: SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute;; 2009.
3. Geiger TR, Peeper DS,: Metastasis mechanisms. Biochim Biophys Acta 2009; 1796: 293-308.
4. Thiery JP, Acloque H, Huang RY, et al.: Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
5. Jechlinger M, Grunert S, Tamir IH, et al.: Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003; 22: 7155-7169.
6. Spaderna S, Schmalhofer O, Hlubek F, et al.: A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006; 131: 830-840.
7. Schimanski CC, Schmitz G, Kashyap A, et al.: Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer. Oncogene 2005; 24: 3100-3109.
8. Spaderna S, Schmalhofer O, Wahlbuhl M, et al.: The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537-544.
9. Shioiri M, Shida T, Koda K, et al.: Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006; 94: 1816-1822.
10. Lohi J,: Laminin-5 in the progression of carcinomas. Int J Cancer J Int Cancer 2001; 94: 763-767.
11. Guess CM, Quaranta V,: Defining the role of laminin-332 in carcinoma. Matrix Biol J Int Soc Matrix Biol 2009; 28: 445-455.
12. Sordat I, Rousselle P, Chaubert P, et al.: Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer J Int Cancer 2000; 88: 708-717.
13. Miyazaki K,: Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 2006; 97: 91-98.
14. Paschos KA, Canovas D, Bird NC,: The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med 2010; 14: 165-174.
15. Paschos KA, Canovas D, Bird NC,: The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 2009; 21: 665-674.
16. Gumbiner BM,: Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6: 622-634.
17. Dorudi S, Hanby AM, Poulsom R, et al.: Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995; 71: 614-616.
18. Delektorskaya VV, Perevoshchikov AG, Golovkov DA, et al.: Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma. Bull Exp Biol Med 2005; 139: 706-710.
19. Han SA, Chun H, Park CM, et al.: Prognostic significance of beta-catenin in colorectal cancer with liver metastasis. Clin Oncol (R Coll Radiol) 2006; 18: 761-767.
20. Suzuki H, Masuda N, Shimura T, et al.: Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res 2008; 28: 1821-1830.
21. Buhmeida A, Elzagheid A, Algars A, et al.: Expression of the cell-cell adhesion molecule beta-catenin in colorectal carcinomas and their metastases. Acta Pathol Microbiol Immunol Scand 2008; 116: 1-9.
22. Choi HN, Kim KR, Lee JH, et al.: Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol Rep 2009; 21: 57-63.
23. Barczyk M, Carracedo S, Gullberg D,: Integrins. Cell Tissue Res 2010; 339: 269-280.
24. Robertson JH, Iga AM, Sales KM, et al.: Integrins: A method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 2008; 14: 296-305.
25. Koretz K, Schlag P, Boumsell L, et al.: Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 1991; 138: 741-750.
26. Gong J, Wang D, Sun L, et al.: Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ Mol Biol J Am Assoc Cancer Res 1997; 8: 83-90.
27. Van Der Bij G, Oosterling S, Bögels M, et al.: Blocking alpha2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth. Hepatology 2008; 47: 532-543.
28. Kitayama J, Nagawa H, Tsuno N, et al.: Laminin mediates tethering and spreading of colon cancer cells in physiological shear flow. Br J Cancer 1999; 80: 1927-1934.
29. Bates RC, Bellovin DI, Brown C, et al.: Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115: 339-347.
30. Wang J, Zhang Z, Xu K, et al.: Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway. Int J Cancer J Int Cancer 2008; 123: 1311-1317.
31. Conti JA, Kendall TJ, Bateman A, et al.: The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation. Clin Cancer Res Off J Am Assoc Cancer Res 2008; 14: 6405-6413.
32. Yoshimura K, Meckel K, Laird L, et al.: Integrin α2 mediates selective metastasis to the liver. Cancer Res 2009; 69: 7320-7328.
33. Holness CL, Simmons DL,: Structural motifs for recognition and adhesion in members of the immunoglobulin superfamily. J Cell Sci 1994; 107: 2065-2070.
34. Brooks SA, Lomax-Browne HJ, Carter TM, et al.: Molecular interactions in cancer cell metastasis. Acta Histochem 2010; 112: 3-25.
35. Hammarstrom S,: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.
36. Ilantzis C, DeMarte L, Screaton RA, et al.: Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia (New York, NY) 2002; 4: 151-163.
37. Samara RN, Laguinge LM, Jessup JM,: Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling. Cancer Res 2007; 67: 4774-4782.
38. Camacho-Leal P, Zhai AB, Stanners CP,: A co-clustering model involving alpha5beta1 integrin for the biological effects of GPI-anchored human carcinoembryonic antigen (CEA). J Cell Physiol 2007; 211: 791-802.
39. Toth CA, Thomas P, Broitman SA, et al.: A new Kupffer cell receptor mediating plasma clearance of carcinoembryonic antigen by the rat. Biochem J 1982; 204: 377-381.
40. Minami S, Furui J, Kanematsu T,: Role of carcinoembryonic antigen in the progression of colon cancer cells that express carbohydrate antigen. Cancer Res 2001; 61: 2732-2735.
41. Aarons CB, Bajenova O, Andrews C, et al.: Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells. Clin Exp Metastasis 2007; 24: 201-209.
42. St Hill CA, Farooqui M, Mitcheltree G, et al.: The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1,6-N- acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas. BMC Cancer 2009; 9: 79.
43. Sperandio M, Thatte A, Foy D, et al.: Severe impairment of leukocyte rolling in venules of core 2 glucosaminyltransferase-deficient mice. Blood 2001; 97: 3812-3819.
44. Tanabe KK, Ellis LM, Saya H,: Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993; 341: 725.
45. Kuhn S, Koch M, Nabel T, et al.: A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007; 5: 553-567.
46. Wong LS, Cantrill JE, Morris AG, et al.: Expression of CD44 splice variants in colorectal cancer. Br J Surg 1997; 84: 363-367.
47. Coppola D, Hyacinthe M, Fu L, et al.: CD44V6 expression in human colorectal carcinoma. Hum Pathol 1998; 29: 627-635.
48. Visse R, Nagase H,: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
49. Zucker S, Vacirca J,: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-117.
50. Pesta M, Holubec L, Topolcan O, et al.: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 2005; 25: 3387-3391.
51. Stein U, Schlag PM,: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007; 176: 61-80.
52. Rudmik LR, Magliocco AM,: Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 2005; 92: 347-359.
53. Delektorskaya VV, Perevoshchikov AG, Golovkov DA, et al.: Prognostic significance of expression of matrix metalloproteinase in colorectal adenocarcinomas and their metastases. Bull Exp Biol Med 2007; 143: 455-458.
54. Golovkov DA,: Key enzymes of the extracellular matrix in colorectal cancer. Bull Exp Biol Med 2009; 147: 353-356.
55. Gentner B, Wein A, Croner RS, et al.: Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 2009; 29: 67-74.
56. Asano T, Tada M, Cheng S, et al.: Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res 2008; 146: 32-42.
57. Dass K, Ahmad A, Azmi AS, et al.: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-136.
58. Stephens RW, Nielsen HJ, Christensen IJ, et al.: Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-874.
59. Nielsen HJ, Pappot H, Christensen IJ, et al.: Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J (Clin Res Ed) 1998; 316: 829-830.
60. Pyke C, Salo S, Ralfkiaer E, et al.: Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995; 55: 4132-4139.
61. Vermeulen PB, Colpaert C, Salgado R, et al.: Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol 2001; 195: 336-342.
62. Illemann M, Bird N, Majeed A, et al.: Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009; 124: 1860-1870.
63. Friedmann Y, Vlodavsky I, Aingorn H, et al.: Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000; 157: 1167-1175.
64. Di Renzo MF, Olivero M, Giacomini A, et al.: Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 1995; 1: 147-154.
65. Herynk MH, Tsan R, Radinsky R, et al.: Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 2003; 20: 291-300.
66. Stein U, Walther W, Arlt F, et al.: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15: 59-67.
67. Lazennec G, Richmond A,: Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med 2010; 16: 133-144.
68. Doll D, Keller L, Maak M, et al.: Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Colorectal Dis 2010; 25: 573-581.
69. Rubie C, Frick VO, Pfeil S, et al.: Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol 2007; 13: 4996-5002.
70. Fulton AM,: The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 2009; 11: 125-131.
71. Zeelenberg IS, Ruuls-Van Stalle L, Roos E,: The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003; 63: 3833-3839.
72. Kim J, Takeuchi H, Lam ST, et al.: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol Off J Am Soc Clin Oncol 2005; 23: 2744-2753.
73. Schimanski CC, Schwald S, Simiantonaki N, et al.: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2005; 11: 1743-1750.
74. Matsusue R, Kubo H, Hisamori S, et al.: Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 2009; 16: 2645-2653.
75. Hu H, Sun L, Guo C, et al.: Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res Off J Am Assoc Cancer Res 2009; 15: 5485-5493.
76. Ghadjar P, Coupland SE, Na IK, et al.: Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2006; 24: 1910-1916.
77. Bessette DC, Qiu D, Pallen CJ,: PRL PTPs: Mediators and markers of cancer progression. Cancer Metastasis Rev 2008; 27: 231-252.
78. Saha S, Bardelli A, Buckhaults P, et al.: A phosphatase associated with metastasis of colorectal cancer. Science (New York, NY) 2001; 294: 1343-1346.
79. Kato H, Semba S, Miskad UA, et al.: High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: A predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res Off J Am Assoc Cancer Res 2004; 10: 7318-7328.
80. Xing X, Peng L, Qu L, et al.: Prognostic value of PRL-3 overexpression in early stages of colonic cancer. Histopathology 2009; 54: 309-318.
81. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Instit 2009; 101: 1308-1324.
82. Pierobon M, Calvert V, Belluco C, et al.: Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 2009; 8: 110-117.
83. Yamada M, Ichikawa Y, Yamagishi S, et al.: Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2008; 14: 2351-2356.
84. Sullivan LA, Brekken RA,: The VEGF family in cancer and antibody-based strategies for their inhibition. mAbs 2010; 2: 165-175. [Epub ahead of print].
85. Berney CR, Yang JL, Fisher RJ, et al.: Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 1998; 18: 973-977.
86. Maeda K, Nishiguchi Y, Yashiro M, et al.: Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000; 5: 373-378.
87. Kuramochi H, Hayashi K, Uchida K, et al.: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2006; 12: 29-33.
88. Thomas M, Augustin H,: The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12: 125-137.
89. Ahmad SA, Liu W, Jung YD, et al.: Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 2001; 92: 1138-1143.
90. Chung YC, Hou YC, Chang CN, et al.: Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 2006; 94: 631-638.
91. Kazerounian S, Yee KO, Lawler J,: Thrombospondins in cancer. Cell Mol Life Sci 2008; 65: 700-712.
92. Sutton CD, O'Byrne K, Goddard JC, et al.: Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin Cancer Res Off J Am Assoc Cancer Res 2005; 11: 6567-6573.
93. Maeda K, Nishiguchi Y, Kang SM, et al.: Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 2001; 8: 763-766.
94. Tokunaga T, Nakamura M, Oshika Y, et al.: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 1999; 79: 354-359.
95. Georgiou L, Minopoulos G, Lirantzopoulos N, et al.: Angiogenesis and p53 at the invading tumor edge: Prognostic markers for colorectal cancer beyond stage. J Surg Res 2006; 131: 118-123.
96. Nanashima A, Shibata K, Nakayama T, et al.: Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma. Ann Surg Oncol 2009; 16: 2130-2137.
97. Toomey D, Murphy J, Conlon K,: COX-2, VEGF and tumour angiogenesis. Surgeon 2009; 7: 174-180.
98. Wang D, Dubois RN,: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2009; 29: 781-788.
99. Soumaoro LT, Uetake H, Higuchi T, et al.: Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2004; 10: 8465-8471.
100. Kobayashi H, Sugihara K, Uetake H, et al.: Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis. Int J Oncol 2009; 34: 1147-1153.
101. Nakamoto RH, Uetake H, Iida S, et al.: Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol 2007; 37: 679-685.
102. Markowitz SD, Bertagnolli MM,: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
103. Kastrinakis W, Ramchurren N, Rieger K, et al.: Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995; 11: 647-652.
104. Heide I, Thiede C, Sonntag T, et al.: The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer (Oxford, England: 1990) 1997; 33: 1314-1322.
105. Peller S, Halevy A, Slutzki S, et al.: p53 Mutations in matched primary and metastatic human tumors. Mol Carcinog 1995; 13: 166-172.
106. de Jong KP, Gouw AS, Peeters PM, et al.: P53 mutation analysis of colorectal liver metastases: Relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res Off J Am Assoc Cancer Res 2005; 11: 4067-4073.
107. Sah NK, Khan Z, Khan GJ, et al.: Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244: 164-171.
108. Lee YY, Yu CP, Lin CK, et al.: Expression of survivin and cortactin in colorectal adenocarcinoma: Association with clinicopathological parameters. Dis Markers 2009; 26: 9-18.
109. Fang Y, Lu Z, Wang G, et al.: Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009; 24: 875-884.
110. Ueno K, Hiura M, Suehiro Y, et al.: Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia (New York, NY) 2008; 10: 697-705.
111. Ueno K, Hazama S, Mitomori S, et al.: Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer 2009; 101: 1374-1381.
112. Carethers JM,: Intersection of transforming growth factor-beta and Wnt signaling pathways in colorectal cancer and metastasis. Gastroenterology 2009; 137: 33-36.
113. Tanaka T, Watanabe T, Kitayama J, et al.: Chromosome 18q deletion as a novel molecular predictor for colorectal cancer with simultaneous hepatic metastasis. Diagn Mol Pathol Am J Surg Pathol B 2009; 18: 219-225.
114. Hahn SA, Schutte M, Hoque AT, et al.: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (New York, NY) 1996; 271: 350-353.
115. Tanaka T, Watanabe T, Kazama Y, et al.: Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A study matched for T- and N-classification. Br J Cancer 2006; 95: 1562-1567.
116. Togo N, Ohwada S, Sakurai S, et al.: Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer. World J Gastroenterol 2008; 14: 4880-4888.
117. Sekiya T, Adachi S, Kohu K, et al.: Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J Biol Chem 2004; 279: 6840-6846.
118. Fritzmann J, Morkel M, Besser D, et al.: A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 2009; 137: 165-175.
119. Bellacosa A, Kumar CC, Di Cristofano A, et al.: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
120. Rychahou PG, Kang J, Gulhati P, et al.: Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 20315-20320.
121. Bardelli A, Siena S,: Molecular mechanisms to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.
122. Cejas P, Lopez-Gomex M, Aguayo C, et al.: KRAS mutation in primary colorectal cancer tumors and related metastases: A potential role in predicition of lung metastasis. PLoS ONE 2009; 4: e1899.
123. Nash GM, Gimbel M, Shia J, et al.: KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010; 17: 572-578.
124. Slaby O, Svoboda M, Michalek J, et al.: MicroRNAs in colorectal cancer: Translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
125. Slaby O, Svoboda M, Fabian P, et al.: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402.
126. Schetter A, Leung S, Sohn J, et al.: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
127. Mudduluru G, Medved F, Grobholz R, et al.: Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 2007; 110: 1697-1707.
128. Asangani IA, Rasheed SA, Nikolova DA, et al.: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136.
129. Xi Y, Formentini A, Chien M, et al.: Prognostic values of microRNAs in colorectal cancer. Biomarker Insights 2006; 2: 113-121.
130. Motoyama K, Inoue H, Takatsuno Y, et al.: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009; 34: 1069-1075.
131. Wang CJ, Zhou ZG, Wang L, et al.: Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 2009; 26: 27-34.
132. Schepeler T, Reinert JT, Ostenfeld MS, et al.: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-6424.
133. Strillacci A, Griffoni C, Sansone P, et al.: MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009; 315: 1439-1447.